Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01445080 · OUTCOME

Pharmacodynamics (PD) Blood Flow Part C

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia · Source last updated 2021-02-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
1 week prior to enrollment, then every 28 days

What was measured

Pharmacodynamics: tumor blood flow in patients with AML and FLT3-ITD mutation using dynamic contrast enhanced MRI (DEMRI) (Part C).

Analysis population: This data were not and will never be collected

Groups in this outcome

Part C: Refractory AML With FLT3-ITD Mutation:150 mg/m^2

Patients receive oral sorafenib 150 mg/m\^2 every 12 hours.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part C: Refractory AML With FLT3-ITD Mutation:150 mg/m^20

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Pharmacodynamics: tumor blood flow in patients with AML and FLT3-ITD mutation using dynamic contrast enhanced MRI (DEMRI) (Part C).
groups
  1. description
    Patients receive oral sorafenib 150 mg/m\^2 every 12 hours.
    id
    OG000
    title
    Part C: Refractory AML With FLT3-ITD Mutation:150 mg/m^2
population Description
This data were not and will never be collected
reporting Status
POSTED
time Frame
1 week prior to enrollment, then every 28 days
title
Pharmacodynamics (PD) Blood Flow Part C
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice